Finding a Clinical Trial: A Guide for Patients
There is a particular kind of conversation that happens in oncology offices and neurology clinics and specialty practices across the country — a conversation that most patients never fully hear. A physician explains that the standard treatments for a condition have been tried, or that the options available carry significant limitations. The patient asks what else is possible. The physician mentions, perhaps briefly, that there may be clinical trials worth looking into.
And then, often, that thread goes nowhere. The patient doesn't know where to look. The physician doesn't have time to conduct a search. The appointment ends. The possibility of a trial — one that might offer access to a treatment that doesn't yet exist anywhere in standard care — recedes into the background.
For a patient whose condition has not responded to standard treatment, or whose diagnosis carries a prognosis that conventional options don't meaningfully change, this missed conversation can matter enormously. Clinical trials are not a last resort or a longshot. For many patients, they are the most promising option available — offering access to treatments that may be more effective than anything currently approved, under the supervision of specialists at leading research institutions.
But finding the right trial, understanding whether a patient qualifies, and navigating the process of accessing it requires knowledge that most patients don't have and most physicians don't have time to provide in a standard appointment. This guide is meant to fill that gap.
What Clinical Trials Actually Are
A clinical trial is a research study that tests a medical intervention — a drug, a device, a procedure, a diagnostic technique, or a combination of approaches — in human participants. The goal of a clinical trial is to determine whether the intervention is safe, effective, or both, in a population of patients who meet specific criteria.
Clinical trials are how every drug that has ever been approved by the FDA got approved. The medications that are now the standard of care for cancer, heart disease, HIV, multiple sclerosis, and virtually every other serious condition were, at some point, experimental treatments being evaluated in a clinical trial. The path from a promising laboratory finding to a widely available treatment runs through clinical research, and patients who participate in trials are not test subjects in the pejorative sense — they are the participants without whom medical progress would not happen.
What distinguishes a clinical trial from standard medical care is the element of research: the intervention being tested has not yet been proven for the specific use being studied, and the goal of the trial is to generate the evidence needed to establish whether it should be. Patients who participate receive the intervention being tested — and also receive careful monitoring, regular follow-up, and access to the specialist care that major research institutions provide.
The Four Phases of Clinical Trials
Clinical trials are conducted in phases, each designed to answer specific questions about an intervention. Understanding the phases helps patients evaluate what a trial is testing and what participating in it would mean.
Phase I trials are the earliest stage of human testing. They typically involve small numbers of participants — often between 20 and 100 — and are primarily designed to evaluate safety: what doses are tolerable, what side effects occur, and how the drug behaves in the human body. Participants in Phase I trials are often patients for whom standard treatments have failed, and these trials may offer access to treatments that are genuinely novel. The unknown element is greater at this stage, since the intervention has not yet been tested extensively in humans.
Phase II trials expand the evaluation to larger groups — typically several hundred patients — and begin to assess whether the intervention shows evidence of effectiveness for the condition being studied. Phase II trials also continue to evaluate safety and to refine the understanding of how the drug works in the relevant patient population. A positive Phase II result is a promising signal, though not yet definitive evidence of efficacy.
Phase III trials are the large-scale studies — often involving hundreds to thousands of patients across multiple institutions — that compare a new intervention against the current standard of care. Phase III trials generate the evidence that regulatory agencies require for approval. Participation in a Phase III trial typically means access to a treatment that has already shown promising results in earlier phases, with the possibility of receiving either the experimental treatment or the best available standard care.
Phase IV trials occur after a drug has been approved and are sometimes called post-marketing studies. They continue to evaluate the drug's safety and effectiveness in the broader patient population, and may explore new uses, dosing regimens, or patient subgroups.
Why Clinical Trials Are Underused — and Why That Matters
Despite the potential benefits, participation rates in clinical trials in the United States are remarkably low. Studies suggest that fewer than 5% of adult cancer patients participate in clinical trials, and rates are even lower for other conditions. The reasons are multiple and interconnected.
Patients don't know trials exist. A patient who isn't told about a trial relevant to their condition cannot seek it out. Oncologists and other specialists are not always up to date on every trial relevant to every patient they see — the clinical trial landscape is vast and changes constantly, and staying current with it while managing a full patient panel is not realistically possible.
Geographic barriers play a role. Major clinical trials are often conducted at academic medical centers and research institutions that may require travel. Patients in rural areas or without access to transportation face practical obstacles that patients near major urban research centers do not.
Eligibility concerns create hesitation. Patients and their physicians may assume, often incorrectly, that a given trial wouldn't accept them — because of age, prior treatment history, or other characteristics. Eligibility criteria are specific and sometimes more accommodating than assumed.
Myths about clinical trials discourage participation in ways that are worth addressing directly.
Common Myths About Clinical Trials
"I'll be a guinea pig." This framing misrepresents how clinical trials work. Every intervention tested in a clinical trial has already been through extensive laboratory and preclinical research before reaching human participants. The oversight structures governing clinical trials — Institutional Review Boards, Data Safety Monitoring Committees, FDA regulation — exist specifically to protect participants. The standard of care provided to trial participants is not less than standard medicine; it is typically more intensive, with more frequent monitoring and more specialist involvement.
"I might get a placebo and receive no treatment." Placebo-only controls are uncommon in oncology and in most serious disease trials. In most cancer trials, every participant receives either the experimental treatment or the current best standard of care — meaning that even participants who don't receive the new drug receive the best available existing treatment. The specific design of a trial — and what each participant can expect to receive — is fully disclosed before enrollment.
"If I join, I'm locked in." Participation in a clinical trial is voluntary, and patients can withdraw at any time. Choosing to leave a trial does not affect the patient's right to continue receiving medical care, and it does not preclude seeking other treatments or other trials.
"Clinical trials are only for people who have run out of options." This was historically a more accurate description than it is today. Increasingly, trials are being designed for patients earlier in their disease course — including patients who have not yet received any treatment — because the goal is to compare new approaches against standard care in patients who haven't been through multiple prior treatment lines. Asking about trial eligibility should be part of the conversation from the time of diagnosis, not reserved for later.
How to Find Clinical Trials
Several resources are available to patients searching for relevant trials, and they serve different purposes.
ClinicalTrials.gov is the comprehensive federal registry of clinical studies conducted in the United States and around the world. It contains information on more than 400,000 studies, searchable by condition, intervention, location, age, and other criteria. The interface can be complex for patients unfamiliar with clinical research terminology, and the sheer volume of results can be overwhelming — but it is the most comprehensive starting point for any search.
The National Cancer Institute maintains its own clinical trials search tool, available at cancer.gov, which is specifically focused on cancer trials and is generally more user-friendly for patients than the full ClinicalTrials.gov database. For patients with cancer diagnoses, this resource is particularly valuable.
The websites of major cancer centers and academic medical centers — Memorial Sloan Kettering, Dana-Farber, MD Anderson, Mayo Clinic, and others — list the trials being conducted at those institutions and often allow patients to search by diagnosis. For patients who are able to travel, accessing a trial at a major research institution also means accessing the specialist care that those institutions provide.
Asking your oncologist or treating specialist directly is important and sometimes underutilized. A physician who is actively involved in research — particularly one at an academic medical center — may be aware of trials not yet widely listed, may have collegial relationships with investigators at other institutions, and may be able to facilitate referral in ways that a self-initiated search cannot.
Disease-specific advocacy organizations — the Leukemia and Lymphoma Society, the National MS Society, the Parkinson's Foundation, and many others — often maintain trial registries and patient navigators who specialize in connecting patients to relevant research opportunities.
How a Medical Navigator Can Help Find the Right Trial
For patients with complex or rare conditions, the clinical trial landscape is often difficult to navigate independently. The search requires understanding the specific eligibility criteria — which depend on detailed knowledge of the patient's diagnosis, prior treatments, laboratory values, and other factors — and evaluating which trials represent the most promising fit given the patient's individual situation.
This is an area where physician-led medical navigation adds substantial value. A navigator with clinical expertise can search the trial landscape systematically, evaluate eligibility with an understanding of the patient's full medical picture, and connect patients with investigators at the relevant institutions in ways that facilitate access rather than simply providing a list.
One case that came to Pilot Rock Medical Navigators involved a patient with a neurological disease for which traditional medicine had no established treatment. In reviewing the case, Pilot Rock identified a clinical trial investigating a new medication for this specific condition — a trial that opened a treatment pathway that would otherwise not have existed for this patient. The identification of that trial required knowledge of the clinical trial landscape, understanding of the patient's specific diagnosis and characteristics, and the ability to evaluate fit between the patient and the trial's eligibility criteria — all of which a comprehensive navigator review provides.
For patients whose condition is rare, whose standard treatment options are limited, or whose disease has progressed despite prior treatment, a systematic clinical trial search conducted by a physician who understands the full clinical picture is one of the most valuable services a medical navigator can provide.
Evaluating Whether a Trial Is Right for You
Once a potentially relevant trial has been identified, several considerations should guide the decision about whether to pursue it.
Understanding the phase of the trial matters for setting expectations. A Phase I trial offers the possibility of access to something novel, with less established data on efficacy. A Phase III trial offers a comparison against the current standard, with more established data and a clearer sense of what outcomes might look like.
The logistics of participation are practical considerations that deserve honest assessment: where the trial is located, how frequently visits are required, what the time commitment looks like, and whether travel, lodging, and time off work are manageable. Many trials offer support for some of these costs, and patient advocacy organizations sometimes provide assistance as well.
The specific eligibility criteria are worth reviewing carefully with a physician who understands both the trial's requirements and the patient's medical profile. What appears on the surface to be a disqualifying factor — a prior treatment, a laboratory value, a co-existing condition — may or may not actually preclude participation, and a physician-to-physician conversation with the trial's investigators can sometimes clarify eligibility in cases where the written criteria leave room for interpretation.
Questions to ask the trial team before enrolling include: What does participation involve, in terms of visits, procedures, and time? What are the known side effects of the experimental treatment, and how are they managed? What happens at the end of the trial — will participants continue to have access to the treatment if it has been beneficial? What are the rights of a participant who chooses to withdraw?
Clinical Trials as Part of a Comprehensive Medical Strategy
The most useful way to think about clinical trials is not as a last resort or an alternative to standard care, but as a component of a comprehensive assessment of all available options — an assessment that should happen at or near the time of diagnosis, not only when standard treatment has failed.
For many conditions, the most innovative and potentially effective treatments are not yet in standard care. They are in trials. And the patients who access those trials — the ones who know to ask, who know where to look, who have someone in their corner to help navigate the search — are the patients who benefit.
Medical navigation exists, in part, to make that access less dependent on luck, geography, and the breadth of any individual physician's knowledge. The clinical trial identified for the Pilot Rock patient with the neurological disease wasn't found in a standard appointment. It was found through a systematic, expert-guided search by someone who knew what to look for — and who was willing to look.
That kind of search is available to every patient. Knowing that it exists is the first step toward taking advantage of it.
__________________
If you or a loved one has a serious condition and wants to know whether a clinical trial might be an option worth exploring, Pilot Rock Medical Navigators can help. Book a free 15-minute introductory call to discuss your situation. Learn how Pilot Rock can help →